StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ALGS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $6.49 | $5.71 | -12.02% | 0.2M |
| 05-18 | $5.81 | $5.36 | -7.75% | 0.2M |
| 05-19 | $5.34 | $5.18 | -3.00% | 0.1M |
| 05-20 | $5.28 | $5.60 | +6.06% | 0.1M |
| 05-21 | $5.59 | $5.71 | +2.15% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.83M | $2.19M | $2.02M | $1.28M |
Operating Income | $-26.93M | $-87.98M | $-66.17M | $-37.81M |
Net Income | $-23.04M | $-24.19M | $-4.31M | $-15.86M |
EPS (Diluted) | $-2.21 | $-2.45 | $-0.44 | $2.90 |
Total Assets | $64.56M | $88.53M | $109.76M | $134.71M |
Total Liabilities | $32.77M | $34.99M | $37.93M | $32.84M |
Cash & Equivalents | $29.98M | $18.30M | $41.95M | $18.66M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 6.19M | 6.18M | 6.15M | 6.15M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.